MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-05-2023
Heska Corporation Operating Income 2011-2026 | HSKA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.3 M | -993 K | -8.19 M | 327 K | 3.79 M | 18.2 M | 16.5 M | 8.56 M | 2.91 M | -1.43 M | 2.16 M | 3.25 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.2 M | -20.3 M | 2.07 M |
Quarterly Operating Income Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | - | -671 K | -5.54 M | -11.5 M | - | -2.43 M | -694 K | 1.02 M | - | 203 K | -4.45 M | -4.62 M | 775 K | 193 K | -566 K | -75 K | 3.31 M | -3.6 M | 2.2 M | 1.87 M | 7.09 M | 3.78 M | 4.56 M | 2.79 M | 6.52 M | 4.49 M | 3.56 M | 1.97 M | 3.56 M | 2.14 M | 1.83 M | 1.02 M | 1.75 M | 341 K | 917 K | -101 K | 2.76 M | 75 K | -3.58 M | -682 K | 720 K | -27 K | 383 K | 1.08 M | 414 K | 408 K | 887 K | 1.54 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.09 M | -11.5 M | 332 K |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.87 | -0.13 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
-113 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DexCom
DXCM
|
912 M | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
CareDx, Inc
CDNA
|
-203 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
-833 M | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 31.19 | 0.73 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
-34.5 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
40 M | $ 13.65 | 9.64 % | $ 335 M | USA |